Phase III, randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor–positive metastatic breast cancer: Updated results of alternative

Stephen R.D. Johnston*, Roberto Hegg, Seock Ah Im, In Hae Park, Olga Burdaeva, Galina Kurteva, Michael F. Press, Sergei Tjulandin, Hiroji Iwata, Sergio D. Simon, Sarah Kenny, Severine Sarp, Miguel A. Izquierdo, Lisa S. Williams, William J. Gradishar

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Fingerprint

Dive into the research topics of 'Phase III, randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor–positive metastatic breast cancer: Updated results of alternative'. Together they form a unique fingerprint.

Medicine & Life Sciences